169 related articles for article (PubMed ID: 20104121)
21. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Moll A; Jäger H; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
HIV Med; 2018 Apr; 19(4):299-307. PubMed ID: 29368456
[TBL] [Abstract][Full Text] [Related]
22. Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center.
Testillano M; Fernandez JR; Suarez MJ; Gastaca M; Bustamante J; Pijoan JI; Montejo M; Valdivieso A; Ruiz P; Gonzalez J; Ortiz de Urbina J
Transplant Proc; 2009 Apr; 41(3):1041-3. PubMed ID: 19376421
[TBL] [Abstract][Full Text] [Related]
23. Rates and predictors of hepatitis C virus treatment in HCV-HIV-coinfected subjects.
Butt AA; Justice AC; Skanderson M; Good C; Kwoh CK
Aliment Pharmacol Ther; 2006 Aug; 24(4):585-91. PubMed ID: 16907891
[TBL] [Abstract][Full Text] [Related]
24. Effects of hepatitis C virus coinfection on survival in veterans with HIV treated with highly active antiretroviral therapy.
Backus LI; Phillips BR; Boothroyd DB; Mole LA; Burgess J; Rigsby MO; Chang SW
J Acquir Immune Defic Syndr; 2005 Aug; 39(5):613-9. PubMed ID: 16044016
[TBL] [Abstract][Full Text] [Related]
25. The effect of HIV viral control on the incidence of hepatocellular carcinoma in veterans with hepatitis C and HIV coinfection.
Kramer JR; Kowalkowski MA; Duan Z; Chiao EY
J Acquir Immune Defic Syndr; 2015 Apr; 68(4):456-62. PubMed ID: 25559606
[TBL] [Abstract][Full Text] [Related]
26. Comorbid diabetes and the risk of progressive chronic kidney disease in HIV-infected adults: data from the Veterans Aging Cohort Study.
Medapalli RK; Parikh CR; Gordon K; Brown ST; Butt AA; Gibert CL; Rimland D; Rodriguez-Barradas MC; Chang CC; Justice AC; He JC; Wyatt CM
J Acquir Immune Defic Syndr; 2012 Aug; 60(4):393-9. PubMed ID: 22592587
[TBL] [Abstract][Full Text] [Related]
27. Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York City metropolitan area.
Bräu N; Bini EJ; Shahidi A; Aytaman A; Xiao P; Stancic S; Eng R; Brown ST; Paronetto F
Am J Gastroenterol; 2002 Aug; 97(8):2071-8. PubMed ID: 12190179
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis C virus increases the risk of kidney disease among HIV-positive patients: Systematic review and meta-analysis.
Fabrizi F; Dixit V; Martin P; Messa P
J Med Virol; 2016 Mar; 88(3):487-97. PubMed ID: 26271205
[TBL] [Abstract][Full Text] [Related]
29. High Proportion of HIV-HCV Coinfected Patients with Advanced Liver Fibrosis Requiring Hepatitis C Treatment in Haiphong, Northern Vietnam (ANRS 12262).
Nguyen Truong T; Laureillard D; Lacombe K; Duong Thi H; Pham Thi Hanh P; Truong Thi Xuan L; Chu Thi N; Luong Que A; Vu Hai V; Nagot N; Tuaillon E; Dominguez S; Lemoine M
PLoS One; 2016; 11(5):e0153744. PubMed ID: 27148964
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of and factors associated with hepatic steatosis in patients coinfected with hepatitis C virus and HIV: Agence Nationale pour la Recherche contre le SIDA et les hépatites virales CO3 Aquitaine Cohort.
Neau D; Winnock M; Castéra L; Bail BL; Loko MA; Géraut L; Dupon M; Ragnaud JM; Lacoste D; Lafon ME; Bioulac-Sage P; Dabis F;
J Acquir Immune Defic Syndr; 2007 Jun; 45(2):168-73. PubMed ID: 17527092
[TBL] [Abstract][Full Text] [Related]
31. Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients.
Lapadula G; Costarelli S; Chatenoud L; Castelli F; Astuti N; Di Giambenedetto S; Quiros-Roldan E; Sighinolfi L; Ladisa N; Di Pietro M; Zoncada A; Di Filippo E; Gori A; Nasta P; Torti C;
J Acquir Immune Defic Syndr; 2015 Jul; 69(3):312-8. PubMed ID: 25723139
[TBL] [Abstract][Full Text] [Related]
32. Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients.
Tural C; Galeras JA; Planas R; Coll S; Sirera G; Giménez D; Salas A; Rey-Joly C; Cirera I; Márquez C; Tor J; Videla S; García-Retortillo M; Clotet B; Solà R
Antivir Ther; 2008; 13(8):1047-55. PubMed ID: 19195330
[TBL] [Abstract][Full Text] [Related]
33. Lack of association between hepatitis C infection and chronic kidney disease.
Asrani SK; Buchanan P; Pinsky B; Rey LR; Schnitzler M; Kanwal F
Clin Gastroenterol Hepatol; 2010 Jan; 8(1):79-84. PubMed ID: 19747988
[TBL] [Abstract][Full Text] [Related]
34. Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct-acting antivirals and antiretroviral therapy.
Liu CH; Sun HY; Hsieh SM; Liu WC; Sheng WH; Liu CJ; Su TH; Tseng TC; Chen PJ; Hung CC; Kao JH
J Viral Hepat; 2021 Jun; 28(6):887-896. PubMed ID: 33759290
[TBL] [Abstract][Full Text] [Related]
35. Comorbidities and their impact on mortality in HCV and HCV-HIV-coinfected persons on dialysis.
Butt AA; Khan UA; Skanderson M
J Clin Gastroenterol; 2008 Oct; 42(9):1054-59. PubMed ID: 19013829
[TBL] [Abstract][Full Text] [Related]
36. Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients?
Verma S; Wang CH; Govindarajan S; Kanel G; Squires K; Bonacini M
Clin Infect Dis; 2006 Jan; 42(2):262-70. PubMed ID: 16355339
[TBL] [Abstract][Full Text] [Related]
37. Validation of the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) chronic kidney disease risk score in HIV-infected patients in the USA.
Mills AM; Schulman KL; Fusco JS; Brunet L; Hsu R; Beyer A; Prajapati G; Mounzer K; Fusco GP
HIV Med; 2020 May; 21(5):299-308. PubMed ID: 31985887
[TBL] [Abstract][Full Text] [Related]
38. In vivo evidence that the cannabinoid receptor 2-63 RR variant is associated with the acquisition and/or expansion of HIV infection.
Sagnelli C; Uberti-Foppa C; Hasson H; Bellini G; Minichini C; Salpietro S; Messina E; Barbanotti D; Merli M; Punzo F; Coppola N; Lazzarin A; Sagnelli E; Rossi F
HIV Med; 2018 Oct; 19(9):597-604. PubMed ID: 29932291
[TBL] [Abstract][Full Text] [Related]
39. Long-term follow-up of elite controllers: Higher risk of complications with HCV coinfection, no association with HIV disease progression.
Stafford KA; Rikhtegaran Tehrani Z; Saadat S; Ebadi M; Redfield RR; Sajadi MM
Medicine (Baltimore); 2017 Jun; 96(26):e7348. PubMed ID: 28658155
[TBL] [Abstract][Full Text] [Related]
40. Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort Study.
Gjærde LI; Shepherd L; Jablonowska E; Lazzarin A; Rougemont M; Darling K; Battegay M; Braun D; Martel-Laferriere V; Lundgren JD; Rockstroh JK; Gill J; Rauch A; Mocroft A; Klein MB; Peters L
Clin Infect Dis; 2016 Sep; 63(6):821-829. PubMed ID: 27307505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
